NATF is striving to reach our 2016 Annual Fund goal, and we're almost there.
Go here to support NATF and help us reach our goal of $250,000.
April 20-22, 2017
Los Angeles, CA
Early Bird Registration Ends December 15
3-Day symposium will bring together medical professionals in fields ranging from cardiology and hematology to pharmacy and family medicine for discussions on current research and evidence-based practices in the field of antithrombotic therapy. In addition to presentations by leading experts, the conference will feature small, topic-specific master classes, a "meet the expert" breakfast, poster sessions and industry exhibits.
For more information and to register, visit acforum2017.org
For this program, entitled 'Pushing the Envelope in Cardiovascular Disease Prevention: Novel Risk Factors, New Therapies, and One Brave Idea', four experts in the field of Thrombosis Medicine will share updates including innovative ways to prevent and treat diabetes and metabolic syndrome, whether a simple blood test can predict your risk of developing cardiovascular disease, new medications to lower cholesterol, and a glimpse into the largest ever research project to cure heart disease.
Offering patients the chance to ask questions, share common concerns, support one another, and learn up-to-date and accurate information about VTE. In upcoming months, we will have alternating physicians serving as moderators for group, each with their own perspective.
Upcoming Support Group Dates:
Wednesday, January 18 - Dr. Geoffrey Barnes
SIGN UP NOW to receive information on how to join a support group.
From smart watches to smart houses, “smart” technology seems to be entering every part of life. In the future, it could even play a role in how patients with thrombosis receive their medications. See more here.
For many years, Warfarin was the only oral anticoagulant commonly used to treat blood clots. In the past five years, the FDA has approved four new oral anticoagulants for the treatment of DVT, PE, and SPAF. Find out the differences between the five FDA-approved oral anticoagulants. View the Chart.
New research out of the University of Otago in New Zealand suggests that chemotherapy could be the cause of increased thrombosis in cancer patients. See more